Raymond James & Associates decreased its position in shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP – Free Report) by 8.1% in the 4th quarter, Holdings Channel reports. The firm owned 7,142 shares of the company’s stock after selling 627 shares during the quarter. Raymond James & Associates’ holdings in Invesco Pharmaceuticals ETF were worth $543,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. grew its position in Invesco Pharmaceuticals ETF by 206.0% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 41,273 shares of the company’s stock valued at $2,987,000 after purchasing an additional 27,786 shares during the period. Horizon Bancorp Inc. IN acquired a new position in shares of Invesco Pharmaceuticals ETF during the third quarter valued at about $59,000. UBS Group AG grew its holdings in shares of Invesco Pharmaceuticals ETF by 132.2% during the third quarter. UBS Group AG now owns 92,123 shares of the company’s stock valued at $6,667,000 after buying an additional 52,455 shares during the last quarter. Finally, Modera Wealth Management LLC bought a new stake in shares of Invesco Pharmaceuticals ETF during the third quarter worth about $538,000.
Invesco Pharmaceuticals ETF Stock Down 0.9 %
Shares of Invesco Pharmaceuticals ETF stock opened at $75.65 on Friday. The company has a market cap of $265.54 million, a PE ratio of 20.52 and a beta of 0.64. Invesco Pharmaceuticals ETF has a 52 week low of $67.75 and a 52 week high of $80.65. The business has a 50 day moving average price of $77.90 and a 200-day moving average price of $74.96.
Invesco Pharmaceuticals ETF Company Profile
PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
Read More
- Five stocks we like better than Invesco Pharmaceuticals ETF
- What is a Secondary Public Offering? What Investors Need to Know
- Hasbro’s Management Made All the Right Calls This Quarter
- ETF Screener: Uses and Step-by-Step Guide
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Investing in large cap stocks: Diving into big caps
- Power Surge: Utilities Sector’s Resilience Shines
Want to see what other hedge funds are holding PJP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invesco Pharmaceuticals ETF (NYSEARCA:PJP – Free Report).
Receive News & Ratings for Invesco Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
